

Mr. Robert M. Sielaty
Compliance Services International
Authorized Agent for Wilbur-Ellis
2001 Jefferson Davis Highway, Suite 1010
Arlington, VA 22202-3603

Dear Mr. Sielaty:

This letter is to transmit Office of Pesticide Programs' (OPP) preliminary human health and ecological risk assessments for the organophosphate (OP) pirimiphos-methyl, for which you hold a registration for technical material. We are providing you with a 30-day period to identify and comment on errors only. Your comments must be received within 30 days of receipt of this letter. The Agency will review and evaluate your comments on errors upon receipt. On or about December 27, 1998, the preliminary risk assessments, your comments and the Agency's review and discussion of your comments will be placed into OPP's Public Docket. The docket will be opened for public comment for 60 days from the date of publication of a Notice of Data Availability in the *Federal Register*. Additionally, the preliminary risk assessments will be placed on the internet at the same time. This process is part of the Agency's efforts to involve the public in the implementation of the Food Quality Protection Act of 1996 and serves as an interim measure to improve the transparency of the reregistration and tolerance reassessment processes.

During this 30-day comment period, the Agency asks for comments on errors, confidential business information (CBI), and planned data. The Agency will respond only to errors which do not pertain to matters of policy, interpretation, or applicability of data. Errors include, but are not limited to, mathematical, computational, typographical, or other similar errors. In the process of reviewing the Agency's preliminary risk assessments, we ask that you inform us in writing of any claims of CBI contained in these assessments. If we do not receive notification in writing of any such claims within 30 days, the Agency will assume that the documents are free of CBI. Also, we request that you inform the Agency of any pertinent, on-going or planned studies, or other sources of information on pirimiphos-methyl, and your timetable for completing and submitting such data and information to the Agency. This will enable the Agency to plan better for refining the risk assessments and completing the reregistration and tolerance reassessment.

If during this thirty day period, you submit comments other than on errors, you should clearly indicate that they are submitted in advance for the 60-day public comment period. You should provide a brief summary of the comments and refer to an attachment which provides a

more in-depth discussion.

Please mail your response, any claims of CBI and other information about pirimiphos-methyl to Lorilyn McKay (CRM). In addition, provide the CRM your response and any supporting material in both hard copy and electronic form. If you have any questions, please contact Lorilyn McKay at (703) 308-8170.

Sincerely,

Arnold Layne, Chief
Reregistration Branch I
Special Review and
Reregistration Division